- conflicts or gaps
- [{"company_slug_format": {"value": "Internal/database slug nabla_bio (underscore) vs YC public slug nabla-bio (hyphen)", "source_urls": ["https://www.ycombinator.com/companies/nabla-bio", "https://yc-oss.github.io/api/batches/summer-2020/nabla-bio.json"]}, "founded_vs_launched": {"value": "YC and TechCrunch cite founding in 2020/May 2020; company press releases describe commercial launch in December 2021", "source_urls": ["https://www.ycombinator.com/companies/nabla-bio", "https://techcrunch.com/2021/12/07/nabla-bio-raises-11m-for-an-end-to-end-antibody-design-platform/", "https://www.businesswire.com/news/home/20240514763517/en/Nabla-Bio-Secures-%2426M-Series-A-Financing-and-Collaborations-with-AstraZeneca-Bristol-Myers-Squibb-and-Takeda-for-Generative-Protein-Design"]}, "headquarters": {"value": "YC lists Boston, MA; company website, BusinessWire, LinkedIn, and Built In consistently cite Cambridge, MA; Dec 2021 seed release dateline was Boston", "source_urls": ["https://www.ycombinator.com/companies/nabla-bio", "https://www.nabla.bio/", "https://www.businesswire.com/news/home/20240514763517/en/Nabla-Bio-Secures-%2426M-Series-A-Financing-and-Collaborations-with-AstraZeneca-Bristol-Myers-Squibb-and-Takeda-for-Generative-Protein-Design", "https://www.businesswire.com/news/home/20211206005050/en/Nabla-Bio-Closes-%2411M-Seed-Financing-led-by-Khosla-Ventures-and-Zetta-Venture-Partners", "https://www.linkedin.com/company/nabla-bio"]}, "employee_count": {"value": "Headcount varies by source and time: YC team size 8 (likely stale), Built In 22, LinkedIn 23, TechCrunch Dec 2021 reported 7", "source_urls": ["https://www.ycombinator.com/companies/nabla-bio", "https://builtin.com/company/nabla-bio", "https://www.linkedin.com/company/nabla-bio", "https://techcrunch.com/2021/12/07/nabla-bio-raises-11m-for-an-end-to-end-antibody-design-platform/"]}, "founders_yc_omission": {"value": "YC Active Founders lists only Surge Biswas and Frances Anastassacos (each duplicated); press identifies George Church as academic co-founder not shown on YC profile", "source_urls": ["https://www.ycombinator.com/companies/nabla-bio", "https://www.businesswire.com/news/home/20211206005050/en/Nabla-Bio-Closes-%2411M-Seed-Financing-led-by-Khosla-Ventures-and-Zetta-Venture-Partners", "https://techcrunch.com/2021/12/07/nabla-bio-raises-11m-for-an-end-to-end-antibody-design-platform/"]}, "pre_seed_amount": {"value": "Fifty Years-led unannounced pre-seed confirmed by TechCrunch but amount not disclosed in primary sources; third-party aggregators report conflicting figures", "source_urls": ["https://techcrunch.com/2021/12/07/nabla-bio-raises-11m-for-an-end-to-end-antibody-design-platform/", "https://www.clay.com/dossier/nabla-bio-funding"]}, "yc_investment_amount": {"value": "No authoritative public source found for standard YC S20 investment amount specific to Nabla Bio", "source_urls": ["https://www.ycombinator.com/companies/nabla-bio", "https://techcrunch.com/2021/12/07/nabla-bio-raises-11m-for-an-end-to-end-antibody-design-platform/"]}, "partnership_value_vs_revenue": {"value": ">$550M (May 2024) and >$1B (Oct 2025 Takeda) figures are potential upfront/milestone/royalty economics, not confirmed realized revenue", "source_urls": ["https://www.businesswire.com/news/home/20240514763517/en/Nabla-Bio-Secures-%2426M-Series-A-Financing-and-Collaborations-with-AstraZeneca-Bristol-Myers-Squibb-and-Takeda-for-Generative-Protein-Design", "https://www.businesswire.com/news/home/20251014934240/en/Nabla-Bio-Signs-Second-Takeda-Collaboration-to-Advance-AI-Driven-Design-of-Protein-Therapeutics", "https://endpoints.news/exclusive-astrazeneca-bms-and-takeda-partner-with-harvard-startup-using-ai-to-make-antibodies/"]}, "takeda_timeline": {"value": "Oct 2025 release says Takeda collaboration since 2022; May 2024 Series A announcement also framed three pharma deals as newly announced strategic collaborations", "source_urls": ["https://www.businesswire.com/news/home/20251014934240/en/Nabla-Bio-Signs-Second-Takeda-Collaboration-to-Advance-AI-Driven-Design-of-Protein-Therapeutics", "https://www.businesswire.com/news/home/20240514763517/en/Nabla-Bio-Secures-%2426M-Series-A-Financing-and-Collaborations-with-AstraZeneca-Bristol-Myers-Squibb-and-Takeda-for-Generative-Protein-Design"]}, "jam_2_validation": {"value": "JAM-2 performance claims based on company preprint and executive interviews; independent clinical validation not yet established; preprint notes future work needed on mechanism-specific design beyond binding", "source_urls": ["https://nabla-public.s3.us-east-1.amazonaws.com/2025_Nabla_JAM2.pdf", "https://endpoints.news/nabla-bio-announces-ai-antibody-model-update-in-jam-2/"]}, "revenue_figures": {"value": "Third-party sites (LinkedIn/Growjo) estimate annual revenue ($4.7M/$1.7M) without primary-company confirmation", "source_urls": ["https://www.linkedin.com/company/nabla-bio", "https://growjo.com/company/Nabla_Bio"]}}]
- source urls
- ["https://builtin.com/company/nabla-bio", "https://endpoints.news/exclusive-astrazeneca-bms-and-takeda-partner-with-harvard-startup-using-ai-to-make-antibodies/", "https://endpoints.news/nabla-bio-announces-ai-antibody-model-update-in-jam-2/", "https://growjo.com/company/Nabla_Bio", "https://medcitynews.com/2021/12/harvard-spinout-nabla-bio-lands-11m-to-bring-ai-technology-to-antibody-design/", "https://nabla-public.s3.us-east-1.amazonaws.com/2025_Nabla_JAM2.pdf", "https://techcrunch.com/2021/12/07/nabla-bio-raises-11m-for-an-end-to-end-antibody-design-platform/", "https://www.businesswire.com/news/home/20211206005050/en/Nabla-Bio-Closes-%2411M-Seed-Financing-led-by-Khosla-Ventures-and-Zetta-Venture-Partners", "https://www.businesswire.com/news/home/20240514763517/en/Nabla-Bio-Secures-%2426M-Series-A-Financing-and-Collaborations-with-AstraZeneca-Bristol-Myers-Squibb-and-Takeda-for-Generative-Protein-Design", "https://www.businesswire.com/news/home/20251014934240/en/Nabla-Bio-Signs-Second-Takeda-Collaboration-to-Advance-AI-Driven-Design-of-Protein-Therapeutics", "https://www.clay.com/dossier/nabla-bio-funding", "https://www.fiercebiotech.com/biotech/takeda-turns-ai-drug-designer-after-whittling-down-rd-focus", "https://www.linkedin.com/company/nabla-bio", "https://www.nabla.bio/", "https://www.nabla.bio/platform", "https://www.pharmaceutical-technology.com/news/nabla-bio-series-a-funding/", "https://www.reuters.com/business/healthcare-pharmaceuticals/us-biotech-nabla-bio-japans-takeda-expand-ai-drug-design-partnership-2025-10-14/", "https://www.ycombinator.com/companies/nabla-bio", "https://yc-oss.github.io/api/batches/summer-2020/nabla-bio.json"]